Arcus Biosciences
Creating Innovative Cancer Immunotherapies
Pipeline
AB928
AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.
AB154
AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.
AB122
AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.
AB680
AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.
Creating Innovative Cancer Immunotherapies